Clinical trials: Hematologic Neoplasms
Hematologic Malignancy
Besponsa Post Marketing Surveillance Study
Besponsa is approved for the treatment of R/R B-cell ALL in Korea. In accordance with the Standards for Re-examination of New Drug, it is required to conduct a PMS.
- Trial name
- NCT04307134
- Testing
- Inotuzumab ozogamicin
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Pfizer
Cancer, Chronic Myelomonocytic Leukemia
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Study and Dose Rationale The safety profile of clofarabine appears acceptable within the target populations studied to date in the clinical studies summarized in Section 2.3.
- Trial name
- NCT00708721
- Testing
- Clofarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Utah
Multiple Myeloma
Autologous Transplant for Multiple Myeloma
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
- Trial name
- NCT00177047
- Testing
- Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan
- Where
- United States
- Volunteers
- 363 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some…
- Conditions
- Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Marginal Zone Lymphoma
- Trial name
- NCT04189952
- Testing
- Acalabrutinib, Rituximab, Ifosfamide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The risk of immunosuppression deters many patients from receiving fludarabine, while combination chemotherapy regimens are poorly tolerated by elderly or infirm chronic lymphocytic leukemia (CLL) patients.
- Trial name
- NCT01113632
- Testing
- Ofatumumab
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- SCRI Development Innovations, LLC
Transplantation, Homologous, Transplantation, Autologous
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.
- Conditions
- Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
- Trial name
- NCT00899847
- Testing
- Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes, Myelodysplastic Syndromes
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
This study is to evaluate the safety and tolerability of vorinostat in combination with decitabine as well as the in vivo molecular and biological effects of vorinostat in patients with refractory or relapsed Acute Myelogenous…
- Trial name
- NCT00479232
- Testing
- vorinostat, decitabine
- Volunteers
- 71 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myelodysplastic Syndrome
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00943800
- Testing
- Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG), Stem Cell Transplant, Stem Cells Collections
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- University of Chicago
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
This phase II trial is studying how well flavopiridol works in treating patients with chronic lymphocytic leukemia or prolymphocytic leukemia.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT00098371
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant.
- Conditions
- Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
- Trial name
- NCT00569309
- Testing
- Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Acute Myeloid Leukemia
Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
Fatigue, reduced quality of life and declines in physical function are common in patients undergoing chemotherapy for acute myeloid leukaemia (AML).
- Trial name
- NCT01170598
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Toronto Rehabilitation Institute
Hematological Malignancies
Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
- Trial name
- NCT04260698
- Testing
- omidubicel
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Leukemia, Chronic Myeloid, Cancer
The EMPATHY Pilot Study
The proposed study, may significantly contribute to improve healthcare delivery in patients with Chronic Myeloid Leukemia (CML) treated with modern tyrosine kinase inhibitors (TKIs) in two ways.
- Trial name
- NCT04384848
- Testing
- EMPATHY Pilot
- Where
- 16 sites in United States, Italy
- Volunteers
- 94 people
- Sponsor
- Northwestern University
Leukemia
Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or…
- Trial name
- CML0206 (NCT00466726)
- Testing
- bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, sargramostim
- Where
- 17 sites in Italy
- Volunteers
- 57 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Neutropenia
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without…
- Trial name
- NCT02190721
- Testing
- tbo-filgrastim
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Multiple Myeloma
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
- Trial name
- NCT00555906
- Testing
- Bortezomib, Dexamethasone, PD 0332991
- Where
- 19 sites in United States, Czechia and 1 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
The primary objectives of this study is to evaluate the safety and efficacy of idelalisib (GS-1101, CAL-101) in participants with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Conditions
- Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT01306643
- Testing
- Idelalisib
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.